AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05984134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NL005 Middle Dose
Description: Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.
Study NCT05984134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NL005 High Dose
Description: Patients in this treatment group will receive NL005 for 1.5 ug/kg respective.Continuous administration for 7 days.
Study NCT05984134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 subjects will be randomly assigned to the placebo for 7 days
Study NCT06132022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala
Description: Mandala work is one of the non-pharmacological approaches and is used to support patients and caregivers in various diseases. Mandala is a method that anyone can apply based on coloring a circular shape.
Study NCT06132022 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: The clinic's routine information will be given to the caregivers of the control group.
Study NCT05177198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-MIST + Clindamycin augmented PRF
Description: modified minimally invasive surgical technique with Clindamycin (at concentration of 150 mg/ml) augmented platelet-rich fibrin.
Study NCT05177198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-MIST + PRF
Description: modified minimally invasive surgical technique with platelet-rich fibrin alone.
Study NCT06440070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop Carpal Tunnel Release
Description: Under the guidance of ultrasound, needles are inserted above and below the transverse carpal ligament, respectively, to form a loop around the ligament. Finally, the ligament is cut by pulling the looped thread.
Study NCT04687956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LYMPHA
Description: Axillary reverse mapping is performed before surgery, axillary lymph node resection is performed, and 'LYMPHA' (Lymphatic microsurgical preventing healing approach) is performed, and the surgery is terminated. Subsequently, the occurrence of lymphedema is followed up.
Study NCT04687956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: In the control group, axillary lymph node resection is performed and the surgery is terminated without additional procedures. Subsequently, the occurrence of lymphedema is followed up.
Study NCT05537233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide up to 1 mg per week in addition to standard closed-loop therapy
Study NCT05537233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection placebo up to 1 mg per week in addition to standard closed-loop therapy
Study NCT05706948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (With Face Mask)
Description: High Intensity Interval Training on Treadmill for 4 weeks with Face mask
Study NCT05706948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (Without Face Mask)
Description: High Intensity Interval Training on Treadmill for 4 weeks with out Face mask
Study NCT05533996 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ultrasound
Description: Sonographic examination to measure the maternal pre-peritoneal fat thickness and subcutaneous fat thickness and calculate body fat index
Study NCT06024070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid Tape
Description: The patient was rested in supine or long sitting position on a table Pre-wrap was applied to cover all the area before tapping Two strips used separately as anchors at the two ends of the pre-wrap. Two Longitudinal stirrup of tape were used from medial side of the superior anchor to lateral side of the same anchor.~Two horizontal stirrup of tape were used from medial side of the distal anchor to lateral side of the same anchor to support the medial side of the foot.~Figure-of-eight straps were utilized for the taping. Lateral heel lock was applied.The tape then proceeded from the lateral side of the foot, looping around the heel, and returning to the same starting point by crossing over the Achilles tendon from behind.~Medial heel lock was applied, the tape application was similar to the lateral heel lock but was at the opposite direction.~Superior and inferior anchors were applied to support all the previous strips
Study NCT06483724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical tourniquet
Description: After opening the abdominal wall, To reduce bleeding during PAS, make the uterine incision above the placenta's intrauterine borders .~2-investigators extract the uterus from the abdomen 3-An assistant slides a sterile Foley catheter (Ch 16/18 French) down to the lowest point and secures it en bloc around the cervix 4-The bladder peritoneum is isolated from the uterus 5-To remove myometrial tissue, leave a margin of at least 2 cm superior to the cervical internal ostium using electrocautery or scissors .
Study NCT06483724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine artery ligation
Description: After opening the abdominal wall, To reduce bleeding during PAS, make the uterine incision above the placenta's intrauterine borders .~2-investigators extract the uterus from the abdomen 3-The bladder peritoneum is isolated from the uterus 4-The uterine vessels were ligated in continuity at the level of the utero-vesical fold on each side 5-To remove myometrial tissue, leave a margin of at least 2 cm superior to the cervical internal ostium using electrocautery or scissors .
Study NCT06301451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General dietary guidance and hydrogen water prepared by portable hydrogen rich water machine
Description: The trial group drink the hydrogen water prepared by the experimental equipment on the basis of receiving general dietary guidance.
Study NCT04936061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolStat active device
Description: The CoolStat active device will administer a therapeutic flow of dry air into the nostril.
Study NCT04936061 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CoolStat sham device
Description: The CoolStat sham device will administer a sham flow of ambient air into the nostril.
Study NCT05065125 — intervention group
Intervention type: DEVICE
Intervention: digital single-operator cholangioscopy
Description: 1. Duodenoscope passes through esophagus and stomach to the papilla of Vater~2. SpyScope DS Catheter passes through the duodenoscope and into common bile duct~3. After direct visualization of anastomosis site stricture, guidewire is passed through SpyScope DS Catheter above the stricture site.
Study NCT04620148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-242
Description: TAK-242 concentrate solution 80 mg/mL for dilution and infusion
Study NCT04620148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo concentrate solution
Study NCT04921319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VExUS score
Description: The care team will be informed of the VExUS immediately after the ultrasound is performed and given a suggested target for the following 24 hours as follows:~* VExUS 0: The patient will likely tolerate more fluid if clinically needed.~* VExUS 1: The patient has evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~* VExUS 2-3: The patient has evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis. If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day.
Study NCT05552898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sleep Study Product Usage
Description: Participants will use their Radicle Sleep study product as directed for a period of 4 weeks.
Study NCT05552898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Study Product Usage
Description: Participants will use their Radicle Sleep study product as directed for a period of 4 weeks.
Study NCT05383157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief mindfulness
Description: Training in mindfulness focused on breathing and pain sensations to enhance decentering, meta-awareness, and interoceptive awareness.
Study NCT05383157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual pain care as delivered in the clinic involving pain assessment and prescription of analgesics.
Study NCT04253717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor control exercise program
Description: Structure physical training aimed at strengthening muscles of the lumbo-pelvic-hip core complex in order to improve stabilization and alignment of the spine and pelvis.
Study NCT04512911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endocardial ablation
Description: Endocardial ablation of VT
Study NCT04512911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endocardial- Epicardial ablation
Description: Epicardial ablation of VT in addition to endocardial ablation
Study NCT04512911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic medications
Description: Addition of anti arrhythmic medication or dose increase
Study NCT04816214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib was available as a film-coated tablet for oral use, with a strength of either 150 mg or 200 mg. The initial dose of the combination therapy consisted of capmatinib 400 mg administered orally twice daily (b.i.d).
Study NCT04816214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib was available as a tablet for oral use, with a strength of either 80 mg or 40 mg. The initial dose of the combination therapy consisted of osimertinib 80 mg administered orally once per day (q.d)
Study NCT04816214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed concentrate for solution for intravenous use was to be administered intravenously. The procurement of pemetrexed was to be done locally, following local practices and regulations.
Study NCT05383157 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual pain care as delivered in the clinic involving pain assessment and prescription of analgesics.
Study NCT04816214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin concentrate for solution for intravenous use was to beadministered intravenously during the study. The procurement of cisplatin was to be done locally, following local practices and regulations.
Study NCT04816214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin concentrate for solution for intravenous use was to be administered intravenously during the study. The procurement of carboplatin was to be done locally, following local practices and regulations.
Study NCT05206149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal glugagon
Description: Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.
Study NCT05206149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Intranasal placebo (represented by isotonic saline solution) is administered.
Study NCT05944679 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: No Xray
Description: Just one Xray 12 months after the intervention
Study NCT05944679 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Xray
Description: Xray at 1, 3, 6 and 12 months after intervention
Study NCT04832373 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Interaction with humanoid robot
Description: A humanoid robot will be installed for 30 days in children. It has a touchscreen tablet, allowing manual interaction complementing the voice interaction. The robot speaks, hears, and has facial and voice identification.
Study NCT05053984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Echoguided Neuromodulation
Description: Once the nerve is located, a needle is introduced in the vicinity of the nerve and is stimulated using an electrical current with a frequency of 10 Hz, with a pulse width of 250 µs and a tolerable intensity causing a visible muscle contraction for 1.5 minutes.
Study NCT05714488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blue halo coil catheter
Description: device inserted with coil at the bladder and straight arm in the prostatic urethra proximal to the external sphincter
Study NCT04710251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Speedometer
Description: We will measure and monitor the withdrawal time of colonoscopy with a speedometer.
Study NCT05902208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiviral treatment with conventional non-surgical treatment
Description: Valaciclovir, a antiviral treatment will be added to the conventional non-surgical treatment of generalized periodontitis. One gram per day will be administered during 28 days.
Study NCT05902208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with conventional non-surgical treatment
Description: Placebo of valaciclovir (same composition, without active substance) will be added to the conventional non-surgical treatment of generalized periodontitis. One gram a day will be administered during 28 days.
Study NCT05090046 — intervention group
Intervention type: OTHER
Intervention: Trauma exposure
Description: Exposure to the Canterbury earthquake sequence and other relevant psychological trauma
Study NCT06037148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DM-101PX
Description: subcutaneous injection of DM-101PX
Study NCT04976192 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TEV-45779
Description: TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe
Study NCT04976192 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: XOLAIR® Injection
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.
Study NCT04976192 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: XOLAIR® Injection
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.
Study NCT06143475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FPS group
Description: Vibration frequency ranged from 0 to 100 Hz. There were 3 modes of FPS application during rehabilitation course. 1) anti-spasticity mode (FV): the stimulators were placed in the middle of the muscles of the affected limb (i.e. unilaterally); 2) bilateral mode of proprioceptive facilitation; and 3) the unilateral mode of the proprioceptive facilitation.~The 2 first sessions were realized with bilateral FPS stimulations plus the anti-spasticity FV mode to reduce the level of hypertonia. Then for 6 consecutive sessions unilateral FPS stimulations of the affected sides imitating the drawing of a straight lines (horizontal, vertical, diagonal), preparing for writing (drawing a circle, triangle, square, spiral) were realized. At last, the 4 remaining FPS sessions were realized unilaterally imitating and promoting the realization of everyday life activities.
Study NCT06143475 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy group
Description: Patients received sessions of traditional physical therapy: individual therapy sessions including exercises to strengthen muscles, stretching, reflex exercises for large, medium and small muscle groups of the upper limbs (ontogeny-oriented kinesiotherapy (OOKT), PNF - proprioceptive neuro-muscle facilitation, training and practice of functional rational self-service tasks). 12 sessions in total were realized 5 times a week and lasted 40 minutes each.
Study NCT05973747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Gluconate
Description: Infused intravenously over 10 minutes upon umbilical cord clamping. First 10 assigned patients received 2 grams per protocol. Subsequent 13 patients received 1.5 grams, dose recalibrated per protocol.
Study NCT05973747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium chloride
Description: 0.5 grams of calcium chloride, infused intravenously over 10 minutes upon umbilical cord clamping
Study NCT06484777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9539 for injection
Description: SHR-9539 for dose escalation/dose extension
Study NCT06478004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct composite restoration of carious primary anterior teeth using custom 3D printed templates
Description: A patient dental model is acquired by digital scan then digital waxing-up is performed using the Exocad software to 3D print clear templates for direct composite resin restoration.
Study NCT06478004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct composite restoration of carious primary anterior teeth using conventional strip crowns
Description: Direct composite resin restoration using celluloid crown forms
Study NCT04545515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed dose combination (FDC) tablets for oral administration.
Study NCT04545515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study NCT06406127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid 600 MG Oral Capsule
Description: Single 600 mg daily dose
Study NCT04990895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Tumour-Specific Patient-Reported Outcomes (ePRO) questionnaires
Description: A web-based portal that prompts participants to enter tumour-specific ePROs at regular intervals in between clinic visits
Study NCT06031571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dry cupping massage
Description: Dry cupping is a form of massage therapy that involves using Hijamat cups without skin injury while applying suction and then performing circular and transverse movements
Study NCT06037148 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Match DM-101PX
Description: Placebo to match DM-101PX administered subcutaneously
Study NCT05378568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the selection scheme of peripheral venous access devices
Description: Based on the Facilitator Toolkit of the promoting action on research implementation in health services integrated framework(i-PARIHS), the implementation plan of peripheral intravenous infusion device selection in hospitalized children was formulated and applied, so as to change the practice behavior of nurses in the intervention group. The specific process mainly includes: tailoring evidence; baseline review; situational analysis; promotion and implementation strategy like lectures, group discussions, operation demonstrations, and scenario simulations.
Study NCT05378568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the existing nursing routine
Description: To choose infusion device according to nurse's working experience. First, nurse placed a peripheral intravenous catheter. The patients and family decide whether to place the central intravenous infusion device according to the recommendation of the medical staff.
Study NCT06192407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oleic Acid Diet
Description: Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is 100% hazelnut oil. They will be taught to consume the oil with each meal and mix it in with the food provided.
Study NCT06192407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Palmitic Acid Diet
Description: Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is palm oil-89%, peanut oil-6.75%, and virgin olive oil-4.25%; . They will be taught to consume the oil with each meal and mix it in with the food provided.
Study NCT06111794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REACH TBI
Description: Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) is a six-session, telephone intervention for Caregivers of Veterans and Services Members with TBI. The intervention focuses on problem solving training, stress management, and psychoeducation. Trained Program Coaches will deliver the REACH TBI intervention by meeting one-on-one via telephone with participants.
Study NCT06111794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REACH TBI
Description: Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) is a six-session, telephone intervention for Caregivers of Veterans and Services Members with TBI. The intervention focuses on problem solving training, stress management, and psychoeducation. Trained Program Coaches will deliver the REACH TBI intervention by meeting one-on-one via telephone with participants.
Study NCT06031571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofacial release
Description: Myofascial release is a form of manual therapy using hands-on techniques to regain tissue extensibility and elasticity
Study NCT04888975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dayspring Active Wearable Compression System
Description: Dayspring Active Wearable Compression System